Search
Menu
Home
Sources
About
Contacts
Ublituximab
Ublituximab
is an
immunomodulator
. It
binds
to
CD20
.
It is
currently
in
Phase 3 clinical trials
for
multiple sclerosis
.
It is also in
Phase 2 clinical trials
for
chronic lymphocytic leukemia
.